Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: illustrative case.

Journal of neurosurgery. Case lessons·2025
Same author

Isolated Lymphomatoid Granulomatosis of the Central Nervous System Mimicking Trigeminal Neuropathy, Bell's Palsy, and Glioblastoma in an Epstein-Barr-Negative Immunocompetent Host: A Case Report.

Cureus·2023
Same author

Postherpetic granulomatous dermatitis occurring in the setting of immune checkpoint inhibitor therapy: A case report.

Journal of cutaneous pathology·2023
Same author

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2022
Same author

Impact of neurofibromatosis type 1 in an adult community population.

Neuro-oncology practice·2022
Same author

Paired Tumor-Germline Testing as a Driver in Better Cancer Care.

JAMA network open·2022

Related Experiment Video

Updated: Jun 18, 2026

Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper
05:45

Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper

Published on: January 19, 2024

Equal care for the elderly with low-grade gliomas?

Amy Pruitt, John W Henson

    Neurology
    |November 13, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
    06:27

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

    Published on: May 9, 2025

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    Related Experiment Videos

    Last Updated: Jun 18, 2026

    Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper
    05:45

    Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper

    Published on: January 19, 2024

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
    06:27

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

    Published on: May 9, 2025

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015